CONNECT1905 is a Phase II, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of Tocilizumab in pediatric and young adult patients with progressive or recurrent adamantinomatous craniopharyngioma (ACP). Tocilizumab is administered intravenously to target the interleukin-6 (IL-6) pathway, which is implicated in the inflammatory tumour microenvironment of ACP. The primary objective is to assess the objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), duration of response, safety, and pharmacokinetics. This study aims to determine whether IL-6 pathway inhibition can provide a novel, targeted treatment approach for patients with ACP, a rare brain tumour with limited therapeutic options following recurrence or progression.